Mon.Nov 15, 2021

article thumbnail

It’s getting harder to launch a new drug to physicians

World of DTC Marketing

SUMMARY: Physicians are tired and overwhelmed with medical information on new drugs. They don’t have the time to sit in the office and search for more information, and they feel that pharma is giving them “too much” information. An exciting development presented itself. A client launched an Oncology drug based on extensive research with physicians, but the results were not that good during a post-launch evaluation.

article thumbnail

The Difference Between a Full Line Sales Rep and an Associate Sales Rep

New to Medical Device Sales

You can listen here: [link] You can watch here: [link] What’s the difference between a full line sales rep (TM ) and an associate sales rep (ASR)? Associate Sales Rep (ASR) The job of an associate rep is to make the full line reps life easier. They will be doing all the things the TM doesn’t want/have time to do. Majority of the times the ASR will be spending their time: Covering cases Running trays/equipment Helping with territory daily task There will be other duties for the ASR, but from my e

Sales 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

A new way to access scientific papers?

Fierce Pharma

A new way to access scientific papers? admin. Mon, 11/15/2021 - 12:01.

147
147
article thumbnail

Hip & knee implant manufacturers – The value creation opportunity

Curzon Consulting

15th November 2021 1 Minutes. If hip and knee implant manufacturers want to stay relevant, and “move the needle” on value creation, they need to play big or go home! An aging (ageing) population is driving absolute sales, but over the past few years, primary hip and knee procedures have become commoditised, which has resulted in margins being squeezed for both hospital providers and implant manufacturers.

article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

3 Practical Steps to Better Protect Your Healthcare Business (and Reputation) from Data Breaches

Nixon Gwilt Law

“.almost every month last year more than 1 million people were affected by data breaches at health-care organizations.” — US Dept of Health and Human Services. Over the past year, the healthcare industry has widely embraced the use of telemedicine and digital health platforms largely as a response to the COVID-19 Public Health Emergency. Not surprisingly, the industry also saw a significant rise in the number of cyberattacks.

article thumbnail

ISO 9000 series requirements in Quality Management Systems : A REVIEW

Pharmatutor

ISO 9000 series requirements in Quality Management Systems : A REVIEW. About Author. Vikas Kumar Prajapati. Organization - Bansal College of Pharmacy, Bhopal(M.P.). Email: vikasprajapati8417@gmail.com. admin. Mon, 11/15/2021 - 16:10. Tags. Articles. Review Articles.

More Trending

article thumbnail

Daniella Gilboa

Cadensee

Daniella Gilboa. CEO, AIVF. CEO of AIVF, a company that is out to transform the fertility and IVF treatment journey. Daniella was an embryologist for more than 15 years before establishing AIVF. . Show Notes. 01:15 What are the most memorable milestones that brought you to where you are today? 02:58 What is the driving force behind your passion for Health Technology?

article thumbnail

National health plan increases competitive overlap to 70% for 900+ Medicare Advantage networks in under 12 months

Clarify Health

Medicare Advantage is expected to reach 40% penetration by 2025. By 2023, available annual profit pools will range from $11 billion to $13 ­billion, making Medicare Advantage the single biggest driver of profit growth for health care insurance providers¹. For health plans looking to grow their share of this market, they need to ensure that [.].